Ascendiant Capital Reiterates Buy on IGC Pharma, Maintains $3.25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital analyst Edward Woo has reiterated a Buy rating on IGC Pharma (AMEX:IGC) and maintained a price target of $3.25.
June 21, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendiant Capital analyst Edward Woo has reiterated a Buy rating on IGC Pharma and maintained a price target of $3.25. This positive analyst rating could boost investor confidence in the short term.
The reiteration of a Buy rating and the maintenance of a $3.25 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100